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Long-Term Complications After Renal Transplantation
L. Martins, A. Ventura, S. Costa, A. Henriques, L. Dias, and A. Sarmento
IN the past, every effort was directed at the prevention ofacute rejection in renal transplant (RT) patients (pts).
Ever since the introduction of the new immunosuppressive
agents in the late 1990s, the short-term results of renal graft
survival are considered satisfactory. In recent years, the
prevention of long-term graft loss and the extension of life
expectancy have gained new emphasis. The immunosup-
pressive agents though, namely calcineurin-inhibitors and
steroids, may potentiate the development of several prob-
lems in RT pts: obesity, hyperglycemia, hyperlipidemia, and
hypertension,1 which are not only risk factors for cardiovas-
cular disease but also for graft loss.2,3
We performed a retrospective analysis of all RTs per-
formed at our unit that reached 10 years (y) with a
functioning graft. The aim of the study was to evaluate
long-term complications and, in view of the results, to seek
a possible strategy that minimizes these problems.
PATIENTS AND METHODS
We analyzed 227 RTs performed between 8 July 1983 and 31
December 1989. The follow-up was truncated at 10 y; the last pt
included completed follow-up on 31 December 1999. The study
group consisted of 107 pts whose kidney grafts were functional at
the end of follow-up.
RESULTS
The overall patient and graft survivals among the 227 pts
was 93.4% and 74.1% at 1 y; 84.6% and 62.1% at 5 y; and
74.9% and 47.1% at 10 y, respectively. Among the 57 pts
who died, 42.1% (24 pts) experienced a cardiovascular
cause of death, including 33.3% (19 pts) with a functional
kidney. The characteristics of the study population and the
immunosuppressive protocol are presented in Table 1. The
mean maintenance doses were: prednisone 10 mg/d; cyclo-
sporine (CyA) 3.7 mg/kg/d; and azathioprine (Aza) 1 mg/
kg/d (or 2 mg/kg/d for pts without CyA).
The prevalence of hypertension, (defined as the fraction
of pts taking antihypertensive medications) at 1 y was
72.9%, including 4.7% who needed two or more drugs to
control blood pressure. The 10-y frequency of hypertension
was similar (77.6%), but 14.9% needed two or more
medications.
Using the National Cholesterol Education Program
Adult Treatment Panel III guidelines,4 the prevalence of
hypercholesterolemia (200 mg/dL) was 63.5% at 1 y
(mean level 219  48 mg/dL); and slightly higher, 73.8%, at
10 y (mean level 230  54 mg/dL). However, hypertriglyc-
eridemia (160 mg/dL) was slightly less prevalent at 10 y
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Table 1. Characteristics of the Study Population (n  107
Patients)
Age on RT date (ys) 34.7  10.3
Male gender 61.6%
First transplant 97.2%
Cadaveric graft 100%
Adults 100%
Immunosuppression (number of patients)
Aza  Steroids 8
CyA  Steroids 71
CyA  Steroids  Aza 14
CyA  Steroids  ATG 5
CyA  Steroids  ATG  Aza 9
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(64.5% vs 61.6% at 1 y), but shared similar mean levels (1
y  166  76; 10 y  170  99 mg/dL). A low HDL-
cholesterol level (40 mg/dL) was observed in 12.1% at 1 y
and 5.6% at 10 y, with similar mean levels (55  21 vs 57 
19 mg 7 dL). A total of 18.7% of patients received
hypolipemic agents. The differences in the lipid profiles
between 1 y and 10 y were not statistically significant.
The body weight increased significantly over the years,
especially between RT and 1 y, namely a mean increment of
6.1  2.8 kg (from 58.8  11.1 to 64.6  12.1 kg, P  .001).
Also, between 1 and 10 y the body weights continued to
increase by 2.6  1.2 kg (mean body weight at 10 y was 67.0
 12.7 kg, P  .006).
After RT, 7.5% of pts became diabetic; 14.9% developed
ischemic heart disease, with chronic heart failure in 5.6%.
Clinically significant peripheral vascular disease occurred in
4.7%, with 3.7% displaying a stroke. Evolution of previous
viral hepatitis resulted in chronic hepatitis in 26.1% (19.6%
due to HCV, 6.5% due to HBV) (Table 2).
Malignancies other than skin localization were observed
in 7.5% of pts. Important infections, excluding UTI, led to
hospitalization in 14%. Bone complaints existed in 33.6%,
including 6.5% who experienced a documented bone frac-
ture. Hyperuricemia with gout occurred in 12.1%. Other
problems (gum hyperplasia, cushingoid appearance, hyper-
trichosis) were noted by 42% of pt. At 10 y the mean serum
creatinine was 1.59  0.53 mg/dL, and the incidence of
proteinuria equal to or greater than 0.5 g/d was 22.4%.
DISCUSSION AND CONCLUSIONS
Long-term complications represent important handicaps
for the global success of RT. We observed a 23.3% inci-
dence of serious cardiovascular problems, which is slightly
higher than that found by Ponticelli et al.5 Indeed, 42.1% of
the RT pts died from a cardiovascular cause before com-
pletion of the 10-y follow-up, including 33.3% who has
functioning grafts. This cause has become the major cate-
gory of late graft loss.6,7
Obesity, which is often associated with the sedentary life
style of these pts, is a known cardiovascular risk factor. We
observed an extremely high weight gain of almost 14% in
10 y. This increment in body weight represented not only
correction of a subnutritional status prior to RT, but an
excessive body weight in most cases. In another study, after
a nutritional evaluation, we found an obesity incidence of
11.4% (body mass index 30 kg/m2) and an overweight
incidence of 41.6% (body mass index 25 and 30 kg/m2)
in our RT pts.
In our unit the prevalence of hepatitis C virus (HCV) and
hepatitis B virus (HBV) infection in RT pts has tended to
decrease, accompanying the international tendency; at
present it is 12.7% and 4.6%, respectively.
Although extremely high, the frequency of hypertension
reported in this study is similar to that published by others.5
Hyperlipidemia also affected almost 70% of pts. These two
complications are still important problems. These compli-
cations associated with long-lasting immunosuppression
may sometimes outweigh the short-term benefit of prevent-
ing acute rejection episodes. Some agents may potentiate
individual cardiovascular risk factors,1 and also represent a
proclivity for graft dysfunction8 and late loss. Especially
after the first year, attention must focus on minimizing
immunosuppressive side effects and controlling nonimmu-
nologic risk factors.1
The judicious screening for pretransplant cardiovascular
disease and the selection of more cardioprotective and
renoprotective immunosuppressive protocols may alter
these findings in the future. Meanwhile, encouraging both
healthy life styles and early and strict control of risk factors
like hypertension, hyperlipidemia, and obesity is mandatory
to optimize transplant outcomes.
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Table 2. Long-Term Complications in 107 RT Patients
1 Year 10 Years
Hypertension 72.9% 77.6%
More than two drugs 4.7% 14.9%
Hypercholesterolemia 63.5% 73.8%
Hypertrigliceridemia 64.5% 61.6%
Low HDL-cholesterol 12.1% 5.6%
Gain of body weight (kg) 6.1  2.8* 2.6  1.2**
Diabetes (post-RT) — 7.5%
Ischemic heart disease — 14.9%
Peripheral vascular disease — 4.7%
Cerebrovascular disease — 3.7%
Chronic hepatitis (HBV, HCV) — 26.1%
*Highly significant since RT day (P  .001).
**Significant since 1 y (P  .006).
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